Share Price and Basic Stock Data
Last Updated: January 3, 2026, 12:22 pm
| PEG Ratio | 878.73 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Sequent Scientific Ltd, operating in the pharmaceuticals sector, reported a market capitalization of ₹9,180 Cr and a share price of ₹210. The company’s revenue has shown modest fluctuations, with sales recorded at ₹1,421 Cr for the fiscal year ending March 2023, a slight increase from ₹1,413 Cr in the previous fiscal year. In the latest quarterly results, sales for June 2023 and September 2023 stood at ₹333 Cr and ₹346 Cr, respectively. Over the next few quarters, sales are expected to rise, reaching ₹390 Cr by June 2024 and ₹402 Cr by March 2025. However, the overall annual sales trajectory indicates a TTM revenue of ₹1,658 Cr, which suggests a potential recovery trajectory post a dip in the fiscal year 2024, where revenue is projected to be ₹1,370 Cr. The company’s ability to navigate the competitive pharmaceutical landscape will be crucial in sustaining and enhancing its revenue growth.
Profitability and Efficiency Metrics
The profitability metrics for Sequent Scientific Ltd reveal a challenging financial landscape. The company reported a net profit of ₹54 Cr with a P/E ratio of 212, indicating high market expectations relative to earnings. Operating profit margins (OPM) have fluctuated, with a low of 1% in March 2022, followed by a recovery to 12% by June 2025. However, the OPM stood at just 1% for the fiscal year 2023, underlining the operational challenges faced. The Interest Coverage Ratio (ICR) at 2.90x signals a moderate ability to meet interest obligations, but it remains a concern given the high debt levels. The cash conversion cycle (CCC) is prolonged at 143 days, indicating inefficiencies in working capital management. Consequently, while there are signs of improving profitability, the company must focus on operational efficiencies to enhance margins and overall profitability.
Balance Sheet Strength and Financial Ratios
Sequent Scientific Ltd’s balance sheet reflects a mixed picture of financial health. The total liabilities reached ₹1,598 Cr, with borrowings amounting to ₹490 Cr, translating to a debt-to-equity ratio of 0.63. This level of leverage is relatively high compared to typical industry standards, which may raise concerns among investors regarding financial stability. On the asset side, the company reported reserves of ₹759 Cr, indicating some cushion against its liabilities. The return on equity (ROE) stood at a low 3.21%, while the return on capital employed (ROCE) was slightly better at 8.47%, suggesting that the company is generating moderate returns on its capital. The book value per share is reported at ₹28.15, with a price-to-book value ratio of 4.65x, signaling that the stock may be overvalued relative to its net assets. This combination of factors emphasizes the need for prudent financial management moving forward.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Sequent Scientific Ltd illustrates a diverse investor base. As of September 2025, promoters held 52.33% of the total shares, reflecting a strong commitment to the company. Institutional investors, including foreign institutional investors (FIIs) and domestic institutional investors (DIIs), accounted for 5.90% and 12.91%, respectively, indicating a moderate level of institutional confidence. The public held 28.69% of shares, showing a significant retail investor interest. Over recent months, there has been a slight decline in promoter holdings, from 52.79% in December 2022 to the current figure, which may raise questions about long-term commitment. Additionally, the number of shareholders has decreased from 1,96,231 in December 2022 to 1,44,085 in September 2025, suggesting a potential concern regarding investor sentiment and confidence, particularly as the company navigates its profitability challenges.
Outlook, Risks, and Final Insight
Looking ahead, Sequent Scientific Ltd faces both opportunities and challenges. The anticipated recovery in sales and improvements in operating margins could position the company for growth if effectively managed. However, persistent high levels of debt and low profitability margins present significant risks that could impede financial stability. The company’s ability to enhance operational efficiencies and reduce its cash conversion cycle will be critical in addressing these concerns. Additionally, fluctuations in the shareholding pattern and declining retail investor interest may impact overall market perception. In a scenario where profitability improves significantly alongside effective debt management, Sequent could emerge as a more attractive investment. Conversely, failure to address its operational inefficiencies and leverage concerns could lead to further declines in investor confidence and market valuation.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 133 Cr. | 106 | 216/84.3 | 29.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,742 Cr. | 435 | 479/192 | 98.2 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.3 Cr. | 47.6 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 53.6 Cr. | 36.6 | 37.0/17.0 | 128 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,248.81 Cr | 1,149.28 | 54.07 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 338 | 375 | 367 | 333 | 346 | 329 | 361 | 390 | 369 | 391 | 402 | 441 | 424 |
| Expenses | 335 | 365 | 370 | 341 | 331 | 307 | 329 | 348 | 330 | 356 | 355 | 389 | 368 |
| Operating Profit | 3 | 10 | -3 | -8 | 15 | 22 | 32 | 42 | 39 | 34 | 46 | 52 | 56 |
| OPM % | 1% | 3% | -1% | -2% | 4% | 7% | 9% | 11% | 11% | 9% | 12% | 12% | 13% |
| Other Income | 1 | 3 | -60 | -23 | 10 | 7 | -1 | 3 | 0 | 6 | 1 | 3 | 0 |
| Interest | 8 | 10 | 11 | 10 | 13 | 13 | 12 | 16 | 14 | 15 | 15 | 14 | 14 |
| Depreciation | 13 | 14 | 15 | 14 | 15 | 15 | 16 | 16 | 17 | 17 | 16 | 15 | 15 |
| Profit before tax | -18 | -10 | -89 | -56 | -3 | 1 | 3 | 12 | 8 | 8 | 16 | 26 | 27 |
| Tax % | -75% | -4% | 4% | -38% | 123% | -617% | 52% | 24% | 20% | 20% | 36% | 31% | 28% |
| Net Profit | -4 | -10 | -92 | -35 | -7 | 11 | 1 | 9 | 6 | 6 | 10 | 18 | 20 |
| EPS in Rs | -0.15 | -0.36 | -3.75 | -1.40 | -0.34 | 0.33 | -0.04 | 0.26 | 0.10 | 0.14 | 0.37 | 0.57 | 0.59 |
Last Updated: December 29, 2025, 5:29 am
Below is a detailed analysis of the quarterly data for Sequent Scientific Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 424.00 Cr.. The value appears to be declining and may need further review. It has decreased from 441.00 Cr. (Jun 2025) to 424.00 Cr., marking a decrease of 17.00 Cr..
- For Expenses, as of Sep 2025, the value is 368.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 389.00 Cr. (Jun 2025) to 368.00 Cr., marking a decrease of 21.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 56.00 Cr.. The value appears strong and on an upward trend. It has increased from 52.00 Cr. (Jun 2025) to 56.00 Cr., marking an increase of 4.00 Cr..
- For OPM %, as of Sep 2025, the value is 13.00%. The value appears strong and on an upward trend. It has increased from 12.00% (Jun 2025) to 13.00%, marking an increase of 1.00%.
- For Other Income, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3.00 Cr. (Jun 2025) to 0.00 Cr., marking a decrease of 3.00 Cr..
- For Interest, as of Sep 2025, the value is 14.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 14.00 Cr..
- For Depreciation, as of Sep 2025, the value is 15.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 15.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 27.00 Cr.. The value appears strong and on an upward trend. It has increased from 26.00 Cr. (Jun 2025) to 27.00 Cr., marking an increase of 1.00 Cr..
- For Tax %, as of Sep 2025, the value is 28.00%. The value appears to be improving (decreasing) as expected. It has decreased from 31.00% (Jun 2025) to 28.00%, marking a decrease of 3.00%.
- For Net Profit, as of Sep 2025, the value is 20.00 Cr.. The value appears strong and on an upward trend. It has increased from 18.00 Cr. (Jun 2025) to 20.00 Cr., marking an increase of 2.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.59. The value appears strong and on an upward trend. It has increased from 0.57 (Jun 2025) to 0.59, marking an increase of 0.02.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:40 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 395 | 443 | 606 | 684 | 848 | 1,039 | 1,179 | 1,362 | 1,413 | 1,421 | 1,370 | 1,551 | 1,658 |
| Expenses | 389 | 425 | 550 | 641 | 765 | 914 | 1,009 | 1,150 | 1,303 | 1,409 | 1,308 | 1,390 | 1,469 |
| Operating Profit | 6 | 18 | 56 | 43 | 83 | 125 | 170 | 212 | 109 | 12 | 61 | 162 | 189 |
| OPM % | 2% | 4% | 9% | 6% | 10% | 12% | 14% | 16% | 8% | 1% | 4% | 10% | 11% |
| Other Income | -54 | 48 | 14 | 9 | 436 | 9 | 10 | -0 | 11 | -58 | -6 | 10 | 10 |
| Interest | 34 | 43 | 38 | 28 | 33 | 33 | 36 | 24 | 16 | 36 | 48 | 61 | 58 |
| Depreciation | 29 | 32 | 46 | 40 | 41 | 42 | 51 | 51 | 52 | 56 | 62 | 66 | 64 |
| Profit before tax | -110 | -8 | -14 | -17 | 444 | 59 | 94 | 137 | 53 | -138 | -55 | 44 | 77 |
| Tax % | 1% | 40% | 19% | -3% | 3% | 3% | 13% | 24% | 15% | -11% | -46% | 27% | |
| Net Profit | -110 | -12 | -16 | -16 | 431 | 57 | 82 | 104 | 45 | -122 | -30 | 32 | 54 |
| EPS in Rs | -8.09 | -0.70 | -0.78 | -0.57 | 17.30 | 1.97 | 2.81 | 3.84 | 1.65 | -4.86 | -1.44 | 0.87 | 1.67 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 1% | 10% | 0% | 13% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 89.09% | -33.33% | 0.00% | 2793.75% | -86.77% | 43.86% | 26.83% | -56.73% | -371.11% | 75.41% | 206.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | -122.42% | 33.33% | 2793.75% | -2880.52% | 130.63% | -17.03% | -83.56% | -314.38% | 446.52% | 131.26% |
Sequent Scientific Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 6% |
| 3 Years: | 3% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 46% |
| 5 Years: | -21% |
| 3 Years: | -19% |
| TTM: | 70% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 6% |
| 3 Years: | 14% |
| 1 Year: | 1% |
| Return on Equity | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 2% |
| 3 Years: | -3% |
| Last Year: | 3% |
Last Updated: September 5, 2025, 1:26 pm
Balance Sheet
Last Updated: December 4, 2025, 1:56 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 27 | 30 | 48 | 49 | 49 | 49 | 50 | 50 | 50 | 50 | 50 | 50 | 50 |
| Reserves | 30 | 61 | 898 | 928 | 599 | 657 | 637 | 678 | 642 | 649 | 607 | 654 | 759 |
| Borrowings | 418 | 473 | 312 | 416 | 305 | 325 | 343 | 277 | 365 | 444 | 488 | 481 | 490 |
| Other Liabilities | 148 | 343 | 265 | 503 | 380 | 346 | 424 | 381 | 378 | 374 | 389 | 412 | 427 |
| Total Liabilities | 623 | 908 | 1,523 | 1,896 | 1,332 | 1,378 | 1,454 | 1,386 | 1,435 | 1,517 | 1,534 | 1,598 | 1,726 |
| Fixed Assets | 238 | 474 | 586 | 684 | 476 | 498 | 577 | 536 | 564 | 605 | 592 | 586 | 628 |
| CWIP | 43 | 39 | 24 | 33 | 18 | 23 | 13 | 31 | 12 | 55 | 16 | 16 | 5 |
| Investments | 0 | 59 | 428 | 428 | 239 | 180 | 171 | 83 | 38 | 0 | 4 | 0 | 0 |
| Other Assets | 342 | 336 | 485 | 751 | 599 | 677 | 693 | 737 | 821 | 856 | 922 | 996 | 1,093 |
| Total Assets | 623 | 908 | 1,523 | 1,896 | 1,332 | 1,378 | 1,454 | 1,386 | 1,435 | 1,517 | 1,534 | 1,598 | 1,726 |
Below is a detailed analysis of the balance sheet data for Sequent Scientific Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 50.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 50.00 Cr..
- For Reserves, as of Sep 2025, the value is 759.00 Cr.. The value appears strong and on an upward trend. It has increased from 654.00 Cr. (Mar 2025) to 759.00 Cr., marking an increase of 105.00 Cr..
- For Borrowings, as of Sep 2025, the value is 490.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 481.00 Cr. (Mar 2025) to 490.00 Cr., marking an increase of 9.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 427.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 412.00 Cr. (Mar 2025) to 427.00 Cr., marking an increase of 15.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,726.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,598.00 Cr. (Mar 2025) to 1,726.00 Cr., marking an increase of 128.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 628.00 Cr.. The value appears strong and on an upward trend. It has increased from 586.00 Cr. (Mar 2025) to 628.00 Cr., marking an increase of 42.00 Cr..
- For CWIP, as of Sep 2025, the value is 5.00 Cr.. The value appears to be declining and may need further review. It has decreased from 16.00 Cr. (Mar 2025) to 5.00 Cr., marking a decrease of 11.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,093.00 Cr.. The value appears strong and on an upward trend. It has increased from 996.00 Cr. (Mar 2025) to 1,093.00 Cr., marking an increase of 97.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,726.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,598.00 Cr. (Mar 2025) to 1,726.00 Cr., marking an increase of 128.00 Cr..
Notably, the Reserves (759.00 Cr.) exceed the Borrowings (490.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -412.00 | -455.00 | -256.00 | -373.00 | -222.00 | -200.00 | -173.00 | -65.00 | -256.00 | -432.00 | -427.00 | -319.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 77 | 95 | 116 | 136 | 111 | 98 | 99 | 93 | 85 | 88 | 89 | 85 |
| Inventory Days | 175 | 153 | 164 | 165 | 125 | 134 | 132 | 139 | 160 | 152 | 166 | 173 |
| Days Payable | 198 | 147 | 175 | 208 | 127 | 141 | 133 | 119 | 119 | 107 | 121 | 115 |
| Cash Conversion Cycle | 54 | 101 | 105 | 93 | 110 | 92 | 98 | 112 | 126 | 132 | 135 | 143 |
| Working Capital Days | -162 | -111 | 65 | -25 | 20 | 33 | 29 | 51 | 54 | 46 | 30 | 70 |
| ROCE % | -4% | 8% | 2% | 1% | 40% | 9% | 12% | 16% | 6% | -3% | 0% | 8% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Small Cap Fund | 22,502,050 | 1.67 | 502.83 | 10,788,925 | 2025-12-07 16:44:07 | 108.57% |
| UTI Healthcare Fund | 871,145 | 1.73 | 19.47 | 620,305 | 2025-12-07 16:44:07 | 40.44% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 0.88 | -1.44 | -4.88 | 1.67 | 3.87 |
| Diluted EPS (Rs.) | 0.85 | -1.44 | -4.88 | 1.65 | 3.85 |
| Cash EPS (Rs.) | 3.94 | 1.28 | -2.66 | 3.87 | 6.24 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 28.15 | 28.58 | 30.04 | 29.44 | 31.26 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 28.15 | 28.58 | 30.04 | 29.44 | 31.26 |
| Revenue From Operations / Share (Rs.) | 61.98 | 54.91 | 56.97 | 56.88 | 54.82 |
| PBDIT / Share (Rs.) | 7.05 | 2.90 | 0.73 | 4.84 | 8.88 |
| PBIT / Share (Rs.) | 4.40 | 0.43 | -1.50 | 2.78 | 6.84 |
| PBT / Share (Rs.) | 1.77 | -2.19 | -5.52 | 2.15 | 5.50 |
| Net Profit / Share (Rs.) | 1.29 | -1.19 | -4.89 | 1.81 | 4.21 |
| NP After MI And SOA / Share (Rs.) | 0.87 | -1.44 | -4.86 | 1.66 | 3.84 |
| PBDIT Margin (%) | 11.37 | 5.28 | 1.29 | 8.51 | 16.18 |
| PBIT Margin (%) | 7.09 | 0.79 | -2.62 | 4.89 | 12.47 |
| PBT Margin (%) | 2.85 | -3.98 | -9.68 | 3.77 | 10.03 |
| Net Profit Margin (%) | 2.07 | -2.16 | -8.58 | 3.18 | 7.67 |
| NP After MI And SOA Margin (%) | 1.41 | -2.61 | -8.52 | 2.91 | 7.00 |
| Return on Networth / Equity (%) | 3.10 | -5.46 | -17.33 | 6.03 | 13.11 |
| Return on Capital Employeed (%) | 10.03 | 1.18 | -3.72 | 7.44 | 18.22 |
| Return On Assets (%) | 1.36 | -2.32 | -7.92 | 2.86 | 6.85 |
| Long Term Debt / Equity (X) | 0.38 | 0.21 | 0.26 | 0.17 | 0.12 |
| Total Debt / Equity (X) | 0.63 | 0.68 | 0.56 | 0.46 | 0.27 |
| Asset Turnover Ratio (%) | 0.98 | 0.89 | 0.17 | 0.17 | 0.20 |
| Current Ratio (X) | 1.73 | 1.31 | 1.50 | 1.54 | 1.55 |
| Quick Ratio (X) | 0.96 | 0.76 | 0.84 | 0.85 | 0.97 |
| Inventory Turnover Ratio (X) | 4.24 | 1.77 | 0.57 | 0.74 | 0.87 |
| Interest Coverage Ratio (X) | 2.90 | 1.50 | 0.51 | 7.62 | 9.04 |
| Interest Coverage Ratio (Post Tax) (X) | 1.61 | 0.74 | -0.61 | 3.86 | 5.65 |
| Enterprise Value (Cr.) | 3717.12 | 3313.78 | 2217.18 | 3626.83 | 6172.31 |
| EV / Net Operating Revenue (X) | 2.40 | 2.42 | 1.56 | 2.57 | 4.53 |
| EV / EBITDA (X) | 21.06 | 45.79 | 120.86 | 30.16 | 28.00 |
| MarketCap / Net Operating Revenue (X) | 2.11 | 2.10 | 1.27 | 2.35 | 4.39 |
| Price / BV (X) | 4.65 | 4.38 | 2.59 | 4.86 | 8.22 |
| Price / Net Operating Revenue (X) | 2.11 | 2.10 | 1.27 | 2.35 | 4.39 |
| EarningsYield | 0.01 | -0.01 | -0.06 | 0.01 | 0.01 |
After reviewing the key financial ratios for Sequent Scientific Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.88. This value is below the healthy minimum of 5. It has increased from -1.44 (Mar 24) to 0.88, marking an increase of 2.32.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.85. This value is below the healthy minimum of 5. It has increased from -1.44 (Mar 24) to 0.85, marking an increase of 2.29.
- For Cash EPS (Rs.), as of Mar 25, the value is 3.94. This value is within the healthy range. It has increased from 1.28 (Mar 24) to 3.94, marking an increase of 2.66.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 28.15. It has decreased from 28.58 (Mar 24) to 28.15, marking a decrease of 0.43.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 28.15. It has decreased from 28.58 (Mar 24) to 28.15, marking a decrease of 0.43.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 61.98. It has increased from 54.91 (Mar 24) to 61.98, marking an increase of 7.07.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 7.05. This value is within the healthy range. It has increased from 2.90 (Mar 24) to 7.05, marking an increase of 4.15.
- For PBIT / Share (Rs.), as of Mar 25, the value is 4.40. This value is within the healthy range. It has increased from 0.43 (Mar 24) to 4.40, marking an increase of 3.97.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.77. This value is within the healthy range. It has increased from -2.19 (Mar 24) to 1.77, marking an increase of 3.96.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.29. This value is below the healthy minimum of 2. It has increased from -1.19 (Mar 24) to 1.29, marking an increase of 2.48.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.87. This value is below the healthy minimum of 2. It has increased from -1.44 (Mar 24) to 0.87, marking an increase of 2.31.
- For PBDIT Margin (%), as of Mar 25, the value is 11.37. This value is within the healthy range. It has increased from 5.28 (Mar 24) to 11.37, marking an increase of 6.09.
- For PBIT Margin (%), as of Mar 25, the value is 7.09. This value is below the healthy minimum of 10. It has increased from 0.79 (Mar 24) to 7.09, marking an increase of 6.30.
- For PBT Margin (%), as of Mar 25, the value is 2.85. This value is below the healthy minimum of 10. It has increased from -3.98 (Mar 24) to 2.85, marking an increase of 6.83.
- For Net Profit Margin (%), as of Mar 25, the value is 2.07. This value is below the healthy minimum of 5. It has increased from -2.16 (Mar 24) to 2.07, marking an increase of 4.23.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 1.41. This value is below the healthy minimum of 8. It has increased from -2.61 (Mar 24) to 1.41, marking an increase of 4.02.
- For Return on Networth / Equity (%), as of Mar 25, the value is 3.10. This value is below the healthy minimum of 15. It has increased from -5.46 (Mar 24) to 3.10, marking an increase of 8.56.
- For Return on Capital Employeed (%), as of Mar 25, the value is 10.03. This value is within the healthy range. It has increased from 1.18 (Mar 24) to 10.03, marking an increase of 8.85.
- For Return On Assets (%), as of Mar 25, the value is 1.36. This value is below the healthy minimum of 5. It has increased from -2.32 (Mar 24) to 1.36, marking an increase of 3.68.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.38. This value is within the healthy range. It has increased from 0.21 (Mar 24) to 0.38, marking an increase of 0.17.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.63. This value is within the healthy range. It has decreased from 0.68 (Mar 24) to 0.63, marking a decrease of 0.05.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.98. It has increased from 0.89 (Mar 24) to 0.98, marking an increase of 0.09.
- For Current Ratio (X), as of Mar 25, the value is 1.73. This value is within the healthy range. It has increased from 1.31 (Mar 24) to 1.73, marking an increase of 0.42.
- For Quick Ratio (X), as of Mar 25, the value is 0.96. This value is below the healthy minimum of 1. It has increased from 0.76 (Mar 24) to 0.96, marking an increase of 0.20.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.24. This value is within the healthy range. It has increased from 1.77 (Mar 24) to 4.24, marking an increase of 2.47.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.90. This value is below the healthy minimum of 3. It has increased from 1.50 (Mar 24) to 2.90, marking an increase of 1.40.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.61. This value is below the healthy minimum of 3. It has increased from 0.74 (Mar 24) to 1.61, marking an increase of 0.87.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,717.12. It has increased from 3,313.78 (Mar 24) to 3,717.12, marking an increase of 403.34.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.40. This value is within the healthy range. It has decreased from 2.42 (Mar 24) to 2.40, marking a decrease of 0.02.
- For EV / EBITDA (X), as of Mar 25, the value is 21.06. This value exceeds the healthy maximum of 15. It has decreased from 45.79 (Mar 24) to 21.06, marking a decrease of 24.73.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.11. This value is within the healthy range. It has increased from 2.10 (Mar 24) to 2.11, marking an increase of 0.01.
- For Price / BV (X), as of Mar 25, the value is 4.65. This value exceeds the healthy maximum of 3. It has increased from 4.38 (Mar 24) to 4.65, marking an increase of 0.27.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.11. This value is within the healthy range. It has increased from 2.10 (Mar 24) to 2.11, marking an increase of 0.01.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has increased from -0.01 (Mar 24) to 0.01, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Sequent Scientific Ltd:
- Net Profit Margin: 2.07%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 10.03% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 3.1% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.61
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.96
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 212 (Industry average Stock P/E: 54.07)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.63
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.07%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 3rd Floor, Srivalli�s Corporate, Hyderabad Telangana 500033 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Kamal K Sharma | Chairman & Ind.Director |
| Mr. Rajaram Narayanan | Managing Director & CEO |
| Mr. Vedprakash Ragate | Executive Director |
| Mr. Gregory Andrews | Non Executive Director |
| Mr. Neeraj Bharadwaj | Non Executive Director |
| Dr. Fabian Kausche | Non Executive Director |
| Dr. Hari Babu Bodepudi | Non Executive Director |
| Mr. Milind Sarwate | Independent Director |
| Ms. Revati Kasture | Independent Director |
FAQ
What is the intrinsic value of Sequent Scientific Ltd?
Sequent Scientific Ltd's intrinsic value (as of 05 January 2026) is ₹178.81 which is 14.85% lower the current market price of ₹210.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹9,180 Cr. market cap, FY2025-2026 high/low of ₹260/111, reserves of ₹759 Cr, and liabilities of ₹1,726 Cr.
What is the Market Cap of Sequent Scientific Ltd?
The Market Cap of Sequent Scientific Ltd is 9,180 Cr..
What is the current Stock Price of Sequent Scientific Ltd as on 05 January 2026?
The current stock price of Sequent Scientific Ltd as on 05 January 2026 is ₹210.
What is the High / Low of Sequent Scientific Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Sequent Scientific Ltd stocks is ₹260/111.
What is the Stock P/E of Sequent Scientific Ltd?
The Stock P/E of Sequent Scientific Ltd is 212.
What is the Book Value of Sequent Scientific Ltd?
The Book Value of Sequent Scientific Ltd is 32.2.
What is the Dividend Yield of Sequent Scientific Ltd?
The Dividend Yield of Sequent Scientific Ltd is 0.00 %.
What is the ROCE of Sequent Scientific Ltd?
The ROCE of Sequent Scientific Ltd is 8.47 %.
What is the ROE of Sequent Scientific Ltd?
The ROE of Sequent Scientific Ltd is 3.21 %.
What is the Face Value of Sequent Scientific Ltd?
The Face Value of Sequent Scientific Ltd is 2.00.